PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
We hypothesize that the efficacy of doxorubicin can be maximized and dose-limiting cardiotoxicity minimized by controlled release from PEGylated nanoparticles. To test this hypothesis, a unique surface modification technique was used to create PEGylated PLGA nanoparticles encapsulating doxorubicin. An avidin-biotin coupling system was used to control PEG conjugation to the surface of PLGA nanoparticles, of diameter ~130 nm, loaded with doxorubicin to 5% w/w. Encapsulation in nanoparticles did not compromise the efficacy of doxorubicin; drug-loaded nanoparticles were found to be at least as potent as free doxorubicin against A20 murine B-cell lymphoma cells in culture and of comparable efficacy against subcutaneously implanted tumors. Cardiotoxicity in mice as measured by echocardiography, serum creatine kinase, and histopathology was reduced for doxorubicin-loaded nanoparticles compared to free doxorubicin. Administration of 18 mg/kg of free doxorubicin induced a 7-fold increase in creatine kinase levels and significant decreases in left ventricular fractional shortening over control animals, whereas of nanoparticle-encapsulated doxorubicin produced none of these pathological changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Current Protocols in Immunology
(2018) · Current Protocols in Immunology · doi:10.1002/(issn)1934-368x · Cited by 3,566
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549 · cited 1×
“advantages are well known and have been demonstrated in previous studies: a wide variety of agents –from extremely hydrophobic to highly hydrophilic [1] – can be encapsulated in PLGA nanoparticles, drug release rates can be tailored to particular applications [2], and size and loading are easily manipulated to provide…”
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617 · cited 1×
“advantages are well known and have been demonstrated in previous studies: a wide variety of agents –from extremely hydrophobic to highly hydrophilic [1] – can be encapsulated in PLGA nanoparticles, drug release rates can be tailored to particular applications [2], and size and loading are easily manipulated to provide…”
Gref, R., Lück, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S., Blunk, T., & Müller, R. H. (2000) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00156-3 · Cited by 1,723
Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,227
Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response
Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., & Young, R. C. (1977) · Science · doi:10.1126/science.877547 · Cited by 1,111
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Current Protocols in Immunology
(2001) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471142735 · Cited by 785
PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats
Li, Y.-P., Pei, Y.-Y., Zhang, X.-Y., Gu, Z.-H., Zhou, Z.-H., Yuan, W.-F., Zhou, J.-J., Zhu, J.-H., & Gao, X.-J. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00218-8 · Cited by 540 · cited 1×
“PLA-PEG) [7], or covalent attachment via amino or carboxyl-terminated PLGA [8], but these methods suffer from drawbacks such as low density or decreased presentation over time.”
Cited by
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
“Considering that numerous reports studying NP PEGylation used NPs prepared by the emulsification method using PVA of various MW and degrees of hydrolysis, it is possible that the outcomes could have been influenced by the residual PVA [207-211], which may partially mask the stealth properties of these PEGylated NPs. X…”
InfluentialPLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
“These therapeutics harness the opportunities provided by nanomaterials to target the delivery of drugs more precisely, in order to improve their solubility, to extend their half-life, to improve their therapeutic index and to reduce their immunogenicit”
BackgroundAdvanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Nanoparticles as drug delivery systems
Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70901-5 · Cited by 1,445
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
“improved targeting efficacy.[105] This has clearly resulted in”
BackgroundPEG — A versatile conjugating ligand for drugs and drug delivery systems
Kolate, A., Baradia, D., Patil, S., Vhora, I., Kore, G., & Misra, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.046 · Cited by 648
PLGA-Based Nanoparticles in Cancer Treatment
Rezvantalab, S., Drude, N. I., Moraveji, M. K., Güvener, N., Koons, E. K., Shi, Y., Lammers, T., & Kiessling, F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01260 · Cited by 607
Oral delivery of anticancer drugs: Challenges and opportunities
Thanki, K., Gangwal, R. P., Sangamwar, A. T., & Jain, S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.020 · Cited by 499
Calzoni, E., Cesaretti, A., Polchi, A., Di Michele, A., Tancini, B., & Emiliani, C. (2019) · Journal of Functional Biomaterials · doi:10.3390/jfb10010004 · Cited by 468
Ibrahim, M., Ramadan, E., Elsadek, N. E., Emam, S. E., Shimizu, T., Ando, H., Ishima, Y., Elgarhy, O. H., Sarhan, H. A., Hussein, A. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.031 · Cited by 465
PEGylation for enhancing nanoparticle diffusion in mucus
Huckaby, J. T., & Lai, S. K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.010 · Cited by 461
Masarudin, M. J., Cutts, S. M., Evison, B. J., Phillips, D. R., & Pigram, P. J. (2015) · Nanotechnology, Science and Applications · doi:10.2147/nsa.s91785 · Cited by 342
Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers
Salmaso, S., & Caliceti, P. (2013) · Journal of Drug Delivery · doi:10.1155/2013/374252 · Cited by 340
Fernandez-Fernandez, A., Manchanda, R., & McGoron, A. J. (2011) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-011-9383-z · Cited by 330
Magnetic core-shell nanoparticles for drug delivery by nebulization
Verma, N. K., Crosbie-Staunton, K., Satti, A., Gallagher, S., Ryan, K. B., Doody, T., McAtamney, C., MacLoughlin, R., Galvin, P., Burke, C. S., et al. (2013) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-11-1 · Cited by 260
Drug delivery vehicles on a nano-engineering perspective
Felice, B., Prabhakaran, M. P., Rodríguez, A. P., & Ramakrishna, S. (2014) · Materials Science and Engineering: C · doi:10.1016/j.msec.2014.04.049 · Cited by 253
Doxorubicin-loaded platelets as a smart drug delivery system: An improved therapy for lymphoma
Xu, P., Zuo, H., Chen, B., Wang, R., Ahmed, A., Hu, Y., & Ouyang, J. (2017) · Scientific Reports · doi:10.1038/srep42632 · Cited by 172
Abd Ellah, N. H., & Abouelmagd, S. A. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1213238 · Cited by 164
The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010) · Nanomedicine · doi:10.2217/nnm.10.113 · Cited by 164
Nanocarriers for targeted drug delivery
Shah, A., Aftab, S., Nisar, J., Ashiq, M. N., & Iftikhar, F. J. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102426 · Cited by 161
The impact of nanoparticle ligand density on dendritic-cell targeted vaccines
Bandyopadhyay, A., Fine, R. L., Demento, S., Bockenstedt, L. K., & Fahmy, T. M. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.12.054 · Cited by 141
“This system leads to prolonged presentation of the biotinylated molecules over the course of several weeks while release of proteins from the PLGA matrix is unhindered [13,18,27].”
Self-citationTian, J., Min, Y., Rodgers, Z., Wan, X., Qiu, H., Mi, Y., Tian, X., Wagner, K. T., Caster, J. M., Qi, Y., et al. (2017) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.11.007 · Cited by 25
Metadata
- Authors
- Park, J., Fong, P. M., Lu, J., Russell, K. S., Booth, C. J., Saltzman, W. M., & Fahmy, T. M.
- Venue
- Nanomedicine: Nanotechnology, Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 5
- Issue
- 4
- Pages
- 410-418
- ISSN
- 1549-9634 (ISSN-L)
- OpenAlex
- W1995650484
- Cited by
- 339
- References
- 22
- FWCI
- 8.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.